Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening, interstitial lung disease
of unknown etiology. The median survival of patients with IPF is only 2 to 3 years, yet some …

Idiopathic pulmonary fibrosis is a devastating, age-related lung disease of unknown cause
that has few treatment options. This disease was once thought to be a chronic inflammatory …

A growing body of evidence indicates that aberrant activation of alveolar epithelial cells and
fibroblasts in an aging lung plays a critical role in the pathogenesis of idiopathic pulmonary …

Importance Current prediction models of mortality in idiopathic pulmonary fibrosis (IPF),
which are based on clinical and physiological parameters, have modest value in predicting …

Pirfenidone is an orally active small molecule that has recently been evaluated in large
clinical trials for the treatment of idiopathic pulmonary fibrosis, a fatal disease in which the …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing lung disorder of
unknown aetiology whose diagnosis involves the careful exclusion of secondary causes for …

In this review, we describe the recent advances in the understanding of the role of
microRNAs in idiopathic pulmonary fibrosis (IPF), a chronic progressive and lethal fibrotic …

Idiopathic pulmonary fibrosis (IPF), the most lethal form of interstitial pneumonia of unknown
cause, is associated with a specific radiological and histopathological pattern (the so-called …

Idiopathic pulmonary fibrosis (IPF) is the most common and most lethal diffuse fibrosing lung
disease, with a mortality rate that exceeds that of many cancers. Recently, there have been …

Molecular biomarkers are highly desired in idiopathic pulmonary fibrosis (IPF), where they
hold the potential to elucidate underlying disease mechanisms, accelerated drug …